Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
GBM
TNBC - Triple-Negative Breast Cancer
NSCLC
Pancreatic Adenocarcinoma
DDR Gene Mutation

Interventions

DRUG: LP-184
DRUG: Olaparib
DRUG: Nivolumab & Ipilimumab

Sponsor

Lantern Pharma Inc.